Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 9Prostatic Neoplasms 9Breast Neoplasms 8Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Urologic Neoplasms 4Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Urethral Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Gallbladder Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Urothelial Carcinoma × Trastuzumab × Genitourinary × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡